United Therapeutics (UTHR) Receivables (2009 - 2026)

United Therapeutics has disclosed Receivables across 18 years of filings, most recently posting $310.3 million for Q2 2026.

• In Q2 2026, Receivables fell 18.19% year-over-year to $310.3 million; the TTM figure through Jun 2026 stood at $310.3 million (down 18.19% YoY), while the FY2025 annual figure was $350.2 million, up 25.38% from the prior year.
• Receivables came in at $310.3 million for Q2 2026 at United Therapeutics, down from $312.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $379.3 million in Q2 2025 to a low of $134.5 million in Q1 2023.
• Average Receivables over 5 years is $274.0 million, with a median of $285.0 million recorded in 2024.
• Year-over-year, Receivables retreated 21.11% in 2023 and jumped 128.48% in 2024.
• Over 5 years, Receivables stood at $220.4 million in 2022, then gained by 26.54% to $278.9 million in 2023, then advanced by 0.14% to $279.3 million in 2024, then rose by 25.38% to $350.2 million in 2025, then decreased by 11.39% to $310.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $310.3 million in Q2 2026, $312.0 million in Q1 2026, and $350.2 million in Q4 2025.